Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 3 Recruiting Academic/Other
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tum…
Sponsor: NRG Oncology
NCT ID: NCT04134260
Sites in Nebraska: - Cancer Partners of Nebraska — Lincoln, Nebraska
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Nebraska: - XCancer Omaha / Urology Cancer Center — Omaha, Nebraska
Phase 3 Recruiting Industry
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Sponsor: Curium US LLC
NCT ID: NCT06235151
Sites in Nebraska: - Great Plains Health, Diagnostic Imaging — North Platte, Nebraska
- XCancer — Omaha, Nebraska
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Nebraska: - NHO Revive Research Institute, LLC — Lincoln, Nebraska
Phase 3 Recruiting Industry
The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06970847
Sites in Nebraska: - XCancer — Omaha, Nebraska
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT06520345
Sites in Nebraska: - XCancer Omaha — Omaha, Nebraska
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
- CHI Health Good Samaritan — Kearney, Nebraska
- Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC — Omaha, Nebraska
Phase 2 Recruiting Network
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in Nebraska: - CHI Health Good Samaritan — Kearney, Nebraska
- Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
- Alegent Health Immanuel Medical Center — Omaha, Nebraska
- Alegent Health Bergan Mercy Medical Center — Omaha, Nebraska
- Alegent Health Lakeside Hospital — Omaha, Nebraska
Phase 2 Recruiting Industry
This is a three-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225). Part 1 will consist of one administration of In-111-rosopatamab tetraxetan to c…
Sponsor: Convergent Therapeutics
NCT ID: NCT06549465
Sites in Nebraska: - X Cancer Omaha / Urology Cancer Center — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT04868604
Sites in Nebraska: - XCancer — Omaha, Nebraska
Phase 2 Recruiting Academic/Other
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06014255
Sites in Nebraska: - XCancer - Omaha, LLC — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Sponsor: Blue Earth Therapeutics Ltd
NCT ID: NCT05413850
Sites in Nebraska: - XCancer Omaha / Urology Cancer Center — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoper…
Sponsor: Radiopharm Theranostics, Ltd
NCT ID: NCT07189871
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
- XCancer — Omaha, Nebraska
Phase 2 Recruiting Academic/Other
The advent of PSMA-PET has improved sensitivity and specificity in staging prostate cancer, particularly in intermediate- and high-risk disease. This has created uncertainty in the management of patients with PSMA-positive but conventional…
Sponsor: University of Nebraska
NCT ID: NCT07237269
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Nebraska: - Exelixis Clinical Site #2 — Omaha, Nebraska
- Exelixis Clinical Site #5 — Omaha, Nebraska
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…
Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Nebraska: - Oncology Hematology West, PC dba Nebraska Cancer Specialists — Omaha, Nebraska
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Nebraska: - Nebraska Cancer Center Oncology Hematology West P.C. — Omaha, Nebraska
Phase 1 Recruiting Industry
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Sponsor: AstraZeneca
NCT ID: NCT06879041
Sites in Nebraska: - Research Site — Omaha, Nebraska
Phase 1 Recruiting Industry
The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter i…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06531499
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
Phase 1 Recruiting Industry
Researchers are looking for a better way to treat participants who have metastatic castration-resistant prostate cancer (mCRPC). mCRPC is a cancer of the prostate (male reproductive gland found below the bladder) that has spread to other p…
Sponsor: Bayer
NCT ID: NCT06217822
Sites in Nebraska: - XCancer Omaha — Omaha, Nebraska
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Nebraska: - CHI Health Saint Francis — Grand Island, Nebraska
- Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
- CHI Health Good Samaritan — Kearney, Nebraska
- Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
- Alegent Health Immanuel Medical Center — Omaha, Nebraska
NA Recruiting Industry
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer di…
Sponsor: Pack Health
NCT ID: NCT05349227
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska